SecBot SecBot

XERS

Xeris Biopharma Holdings, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001867096 Biotech & Drug Discovery
$16.70 +0.04 (+0.24%)
Nov 16 4:00 PM ET · prev $16.66
Market cap
$3.0B
Mid cap
Consensus
Buy
85% Buy or better · 13 analysts
Median target
$18.00
+8% · range $12.00–21.00
1 year
+130.0%
from $7.26 · Nov 17
30 days
+52.5%
from $10.95
52-week range
$5.29–16.70
at the high
Avg volume 20D
3.38M
Nov 5 spike 12.60M
Short interest
8.99M
≈4.9% of shares · +11.9%
Days to cover
4.3
at average volume
Insider net
−$4.1M
0 buyers · 8 sellers · since Mar 2
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
25
analyzed by SecBot
SecBot read BULLISH 13 reports · 90 days
Balance 0 bearish · 2 bullish · 11 neutral oldest → newest, height = score
Avg score ·High conf. 11/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Mar 2 ▼ 1 insider sell $104.1K at $6.25
  • Mar 30 to Apr 1 ▼ 2 days of insider sells: $159.9K by 2 insiders, avg $5.81
  • May 1 ▼ 1 insider sell $103.8K at $6.23
  • Jun 1 to Jun 4 ▼ 3 days of insider sells: $503.2K by 5 insiders, avg $6.05
  • Jul 1 to Jul 7 ▼ 3 days of insider sells: $1.2M by 3 insiders, avg $8.17
  • Aug 3 ▼ 2 insiders sell $253.8K at $8.01
  • Aug 12 ▼ 1 insider sell $42.5K at $8.50
  • Sep 1 ▼ 3 insiders sell $311.2K at $8.49
  • Sep 28 to Oct 1 ▼ 2 days of insider sells: $594.9K by 3 insiders, avg $9.65
  • Nov 2 to Nov 5 ▼ 2 days of insider sells: $772.7K by 3 insiders, avg $11.04
  • Nov 5 ▲ Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and abov…
  • Nov 5 ▲ Earnings: XERS Q3 2026 Earnings: EPS $0.06 (+144.9% vs est)

Signal stack

Where each data set points today.

  • InsidersBEARISH

    8 insiders sold $4.1M.

  • InstitutionsBULLISH

    Q3 2026: 30 added (2 new), 16 trimmed or exited.

  • AnalystsBULLISH

    11 of 13 rate it Buy or better. Median target $18.00 (+8%).

  • EstimatesRISING

    Current-quarter EPS estimate $0.055 → $0.070 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +11.9% to 8.99M shares. 4.3 days to cover, ≈4.9% of shares.

  • TrendUPTREND

    58% above its 50-day average. New closing high $16.70 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 6.

Who's buying

13F· Q3 2026
2
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & CODOUBLED2,381,573$23.8M
DIMENSIONAL FUND ADVISORS LPADD1,695,568$16.2M
FIRST TRUST ADVISORS LPDOUBLED1,403,607$13.4M
HRT FINANCIAL LPDOUBLED1,083,894$10.4M
FMR LLCADD1,026,022$9.8M
UBS Group AGTRIM787,325$7.5M
ROYCE & ASSOCIATES LPADD588,178$5.6M
BNP PARIBAS FINANCIAL MARKETSADD553,444$5.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 85% rate it Buy or better
Strong Buy5Buy6Hold2Sell0Strong Sell0
12-month targets · 7 analysts

Price is inside the target range. Median implies +8%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 6, 2026Oppenheimer
REITERATE
REITERATEOutperform
Nov 6, 2026Piper Sandler
REITERATE
REITERATENeutral
Nov 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 6, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 10, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$4.1M
sold · 8 insiders
DateInsiderTypeValue
Nov 5, 2026
McCulloch Kevin
See Remarks
Nov 5, 2026
SELL$312.2K
Nov 2, 2026
Pieper Steven
See Remarks
Nov 2, 2026
SELL$51.2K
Nov 2, 2026
Hecht Beth
See Remarks
Nov 2, 2026
SELL$255.8K
Nov 2, 2026
Taddese Menassie
Director
Nov 2, 2026
AWARD$320.3K
Nov 2, 2026
Taddese Menassie
Director
Nov 2, 2026
AWARD22,365 sh
Nov 2, 2026
McCulloch Kevin
See Remarks
Nov 2, 2026
SELL$153.5K
Oct 1, 2026
Pieper Steven
See Remarks
Oct 1, 2026
SELL$47.0K
Oct 1, 2026
Hecht Beth
See Remarks
Oct 1, 2026
SELL$156.8K

Earnings setup

Estimates
$0.07
EPS estimate, this quarter
+27%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.07$0.06–$0.08+110.0%$119.0M
Next Q$0.03$0.02–$0.04+20.0%$115.9M
Current FY-$0.01-$0.04–$0.03+85.2%$401.5M
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
8,986,870
shares short
+11.9%
vs prior settlement
4.3
days to cover
≈4.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 SEC
Three Xeris insiders sold a total of $619K in open-market sales over a week, including a sale by Kevin McCulloch the…
CLUSTER · Impact 2/10
Nov 5, 2026 SEC
Kevin McCulloch, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 25,000 shares of common…
144 · Impact 2/10
Nov 5, 2026 SEC
Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and above the $101.7M consensus, driven by Recorlev net…
8-K · Impact 6/10
Nov 5, 2026 Insider
McCulloch Kevin sold 25,000 shares
See Remarks @ $12.49 ($312.2K)
Nov 5, 2026 Earnings result
XERS Q3 2026 Earnings: EPS $0.06 (+144.9% vs est)
Nov 2, 2026 Insider
Pieper Steven sold 5,000 shares
See Remarks @ $10.23 ($51.2K)
Nov 2, 2026 Insider
Hecht Beth sold 25,000 shares
See Remarks @ $10.23 ($255.8K)
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · DOUBLED
2,381,573 shares ($23.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

25 filings · 4 bullish · 1 bearish · 20 neutral
All XERS filing & press-release reports (25)